Aspen Pharmacare (APNHY) AI Stock Analysis

Aspen Pharmacare

(Other OTC:APNHY)

Select Model

Rating:77Outperform

Price Target:$11.00▲(16.32% Upside)

Action:upgraded

Date:09/15/26

Strong earnings guidance and solid balance sheet are the primary drivers, complemented by positive technical indicators, while valuation remains neutral.

Positive Factors

Deleveraging and net cashMaterial deleveraging and a net cash position strengthen Aspen’s financial resilience and reduce interest and refinancing pressure. This gives management greater flexibility to fund manufacturing growth, support commercial expansion, and allocate capital without relying heavily on additional borrowing.

Negative Factors

Revenue contraction and weaker returnsThe revenue decline shows that Aspen’s earnings rebound has not yet been matched by durable top-line growth. Lower margins than in earlier years and modest ROE also indicate weaker profit efficiency, which could limit the sustainability of shareholder returns if growth remains subdued.

Aspen Pharmacare (APNHY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.17B
Dividend Yield: 1.45%
Average Volume (3M): 3,167
Price to Earnings (P/E): 26.5
Beta (1Y): 0.21
Revenue Growth: -13.45%
EPS Growth: ―
Country: US
Employees: 7,625
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Aspen Pharmacare Business Overview & Revenue Model

Company Description

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Phar...

How the Company Makes Money

Aspen Pharmacare makes money primarily by selling pharmaceutical products and by providing pharmaceutical manufacturing services. A key revenue stream is the commercial sale of medicines—Aspen earns revenue when it sells its owned or licensed brands...

Aspen Pharmacare Earnings Call Summary

Earnings Call Date:Sep 01, 2026(Q4-2026)|% Change Since:-1.79%|Next Earnings Date:Mar 10, 2027

Earnings Call SentimentPositive

The call was strongly positive. Management highlighted 14% group normalized EBITDA growth, 28% NHEPS growth, ZAR 3.8 billion of free cash flow, a net cash position, successful recovery of the sterile manufacturing business and guidance for at least ZAR 9 billion of EBITDA and more than 50% NHEPS growth in financial year 2027. These positives outweighed the flat group revenue, manufacturing revenue decline, restructuring and impairment charges, geopolitical effects and near-term Canadian GLP-1 API uncertainty.

Positive Updates

Commercial Pharma EBITDA Growth

Commercial Pharma delivered 13% EBITDA growth in constant exchange rate, extending double-digit growth from financial year 2025. Growth was supported by organic growth in emerging markets and the China reshape program.

Negative Updates

Flat Group Revenue

Group revenue was flat in constant exchange rate, with Commercial Pharma growth offset by a decline in Manufacturing revenue.

Company Guidance

For financial year '27, Aspen expects the commercial pharma base business to grow in mid-single digits, both in revenue and EBITDA, manufacturing revenue growth of greater than 50%, manufacturing EBITDA to more than double financial year '26 EBITDA, and sterile finished dose form EBITDA of ZAR 2.2 billion, with sterile finished dose form achieving positive EBITDA; normalized EBITDA is guided to at least ZAR 9 billion, with the intention to get at least a further ZAR 1.3 billion, implying more than 50% growth in NHEPS, while stronger free cash flow, stable capital investment, sustained working capital focus, tax rates of 24%, 25%, and commencement of GLP-1s will be additive, with a global GLP-1 rollout to contribute substantially not included in this guidance; Mounjaro sales are expected to be more than ZAR 2 billion.

Aspen Pharmacare Financial Statement Overview

Summary

Strong balance sheet deleveraging and healthy cash generation provide stability, though revenue decline weighs on the income statement.

Income Statement

58Neutral

Balance Sheet

84Very Positive

Cash Flow

77Positive

Financial statement breakdown
Breakdown	TTM	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022
Income Statement
Total Revenue	34.66B	34.14B	43.36B	44.71B	40.71B	38.61B
Gross Profit	13.93B	13.76B	19.13B	19.42B	18.41B	18.31B
EBITDA	7.23B	7.16B	3.62B	9.90B	10.72B	10.45B
Net Income	2.62B	2.59B	-1.08B	4.40B	5.23B	6.49B
Balance Sheet
Total Assets	107.41B	107.41B	135.89B	139.16B	134.28B	111.38B
Cash, Cash Equivalents and Short-Term Investments	15.87B	15.87B	6.41B	12.34B	10.91B	6.18B
Total Debt	15.44B	15.44B	36.12B	36.46B	29.28B	22.25B
Total Liabilities	27.68B	27.68B	51.00B	54.29B	48.05B	40.43B
Stockholders Equity	79.73B	79.73B	84.89B	84.86B	86.24B	70.94B
Cash Flow
Free Cash Flow	4.83B	4.63B	104.00M	690.00M	2.34B	2.68B
Operating Cash Flow	7.02B	6.73B	5.16B	6.22B	5.52B	5.37B
Investing Cash Flow	25.20B	23.83B	-5.22B	-9.47B	-3.42B	-2.16B
Financing Cash Flow	-22.00B	-20.86B	-162.00M	3.62B	-420.00M	-4.68B

Aspen Pharmacare Technical Analysis

Technical Analysis SentimentNeutral

Last Price9.46

Price Trends

50DMA9.54Negative

100DMA9.28Positive

200DMA8.61Positive

Market Momentum

MACD0.01Positive

RSI48.05Neutral

STOCH45.52Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APNHY, the sentiment is Neutral. The current price of 9.46 is below the 20-day moving average (MA) of 9.53, below the 50-day MA of 9.54, and above the 200-day MA of 8.61, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.05 is Neutral, neither overbought nor oversold. The STOCH value of 45.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APNHY.

Aspen Pharmacare Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

APNHY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APNHY	77Outperform	$4.07B	26.51	3.28%	1.45%	-13.45%	―
RDY	67Neutral	$11.87B	40.24	7.37%	0.59%	-10.52%	-55.45%
TEVA	65Neutral	$47.43B	70.17	9.18%	―	4.40%	―
VTRS	63Neutral	$21.86B	-52.88	-2.79%	2.52%	4.92%	87.81%
AMRX	59Neutral	$7.49B	43.24	-326.75%	―	9.28%	4917.17%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	46Neutral	$2.19B	-1.26	-55.97%	7.35%	-4.18%	-2138.82%

* Healthcare Sector Average

Performance Comparison

APNHY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
APNHY	Aspen Pharmacare	9.46	3.87	69.15%
RDY	Dr. Reddy's Laboratories Ltd	14.17	0.83	6.25%
VTRS	Viatris, Inc.	19.04	8.87	87.19%
PRGO	Perrigo Company	15.78	-2.98	-15.89%
TEVA	Teva Pharmaceutical Industries Limited	42.09	23.59	127.51%
AMRX	Amneal Pharma	21.51	10.32	92.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 15, 2026

Aspen Pharmacare AI Stock Analysis